Eli Lilly and Company (NYSE:LLY) Cut to “Hold” at Wall Street Zen

Wall Street Zen cut shares of Eli Lilly and Company (NYSE:LLY) from a buy rating to a hold rating in a report issued on Saturday morning,Wall Street Zen reports.

Several other equities research analysts also recently issued reports on the company. BMO Capital Markets reaffirmed an “outperform” rating on shares of Eli Lilly and Company in a research report on Thursday, October 1st. Wells Fargo & Company boosted their price objective on Eli Lilly and Company from $1,280.00 to $1,330.00 and gave the stock an “overweight” rating in a research report on Thursday, August 6th. Truist Financial boosted their price objective on Eli Lilly and Company from $1,370.00 to $1,376.00 and gave the stock a “buy” rating in a research report on Friday, August 7th. Sanford C. Bernstein increased their target price on Eli Lilly and Company from $1,300.00 to $1,385.00 and gave the company an “outperform” rating in a research note on Tuesday, July 14th. Finally, Cantor Fitzgerald increased their target price on Eli Lilly and Company from $1,410.00 to $1,440.00 and gave the company an “overweight” rating in a research note on Thursday, October 8th. One analyst has rated the stock with a Strong Buy rating, twenty-four have issued a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $1,313.43.

Eli Lilly and Company Price Performance

NYSE LLY opened at $1,242.76 on Friday. The company has a current ratio of 1.35, a quick ratio of 1.00 and a debt-to-equity ratio of 1.41. The company has a fifty day simple moving average of $1,180.34 and a 200 day simple moving average of $1,111.84. The company has a market cap of $1.17 trillion, a P/E ratio of 39.92, a P/E/G ratio of 1.67 and a beta of 0.46. Eli Lilly and Company has a 1 year low of $793.82 and a 1 year high of $1,292.65.

Eli Lilly and Company (NYSE:LLY) last posted its earnings results on Wednesday, August 5th. The company reported $8.38 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $6.40 by $1.98. The business had revenue of $22.97 billion for the quarter, compared to analyst estimates of $20.82 billion. Eli Lilly and Company had a net margin of 33.53% and a return on equity of 97.83%. Eli Lilly and Company’s revenue was up 47.7% compared to the same quarter last year. During the same period last year, the business posted $6.31 EPS. Eli Lilly and Company has set its FY 2026 guidance at 35.500-36.500 EPS. On average, sell-side analysts predict that Eli Lilly and Company will post 33.56 EPS for the current year.

Insiders Place Their Bets

In other Eli Lilly and Company news, CAO Donald Zakrowski sold 2,000 shares of the firm’s stock in a transaction on Monday, August 10th. The shares were sold at an average price of $1,185.01, for a total value of $2,370,020.00. Following the sale, the chief accounting officer directly owned 1,526 shares in the company, valued at $1,808,325.26. This trade represents a 56.72% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Anat Hakim sold 5,000 shares of the business’s stock in a transaction dated Friday, August 7th. The stock was sold at an average price of $1,190.00, for a total transaction of $5,950,000.00. Following the transaction, the executive vice president owned 11,875 shares in the company, valued at approximately $14,131,250. The trade was a 29.63% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 13,500 shares of company stock worth $15,958,170 in the last ninety days. Insiders own 0.14% of the company’s stock.

Institutional Investors Weigh In On Eli Lilly and Company

Hedge funds have recently made changes to their positions in the stock. Secure Asset Management LLC boosted its stake in shares of Eli Lilly and Company by 5.7% during the 3rd quarter. Secure Asset Management LLC now owns 7,181 shares of the company’s stock worth $8,309,000 after acquiring an additional 389 shares during the last quarter. Peirce Capital Management LLC increased its stake in shares of Eli Lilly and Company by 7.2% in the 3rd quarter. Peirce Capital Management LLC now owns 432 shares of the company’s stock worth $500,000 after purchasing an additional 29 shares in the last quarter. Blue Zone Wealth Advisors LLC increased its stake in shares of Eli Lilly and Company by 9.1% in the 3rd quarter. Blue Zone Wealth Advisors LLC now owns 191 shares of the company’s stock worth $221,000 after purchasing an additional 16 shares in the last quarter. Arlington Financial Advisors LLC increased its stake in shares of Eli Lilly and Company by 11.2% in the 3rd quarter. Arlington Financial Advisors LLC now owns 565 shares of the company’s stock worth $654,000 after purchasing an additional 57 shares in the last quarter. Finally, Maia Wealth LLC raised its holdings in Eli Lilly and Company by 3.8% in the 3rd quarter. Maia Wealth LLC now owns 6,360 shares of the company’s stock worth $7,359,000 after purchasing an additional 234 shares during the period. Institutional investors own 82.53% of the company’s stock.

More Eli Lilly and Company News

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Omvoh delivered positive pediatric trial results. In the Phase 3 SHINE-2 study, 81% of children with moderately to severely active ulcerative colitis achieved a clinical response after induction, while half of responders reached clinical remission after one year. Lilly plans to submit the data to regulators for a potential pediatric label expansion. Lilly Omvoh pediatric ulcerative colitis trial results
• Positive Sentiment: Foundayo and the broader GLP-1 franchise remain key growth drivers. European regulators recommended approval of Lilly’s oral weight-loss treatment Foundayo, while analysts expect it to continue gaining market share. Strong GLP-1 sales are also expected to support upcoming third-quarter results. European Union regulators recommend Foundayo approval
• Positive Sentiment: Lilly expanded its drug-delivery capabilities. The company signed a collaboration with Metis TechBio valued at up to $1.1 billion, potentially accelerating development of AI-enabled drug-delivery technology. Metis TechBio drug-delivery collaboration
• Neutral Sentiment: Lilly will present updates on several oncology candidates at the ESMO Congress, including treatments targeting ovarian, lung, thyroid and breast cancers. The data could broaden the company’s growth base, although the commercial impact remains dependent on clinical and regulatory outcomes. Lilly oncology pipeline ESMO update
• Negative Sentiment: Competition, valuation and legal exposure are weighing on sentiment. Investors are monitoring a potential GLP-1 price war with Novo Nordisk and Lilly’s dependence on a concentrated weight-loss portfolio. A Pennsylvania lawsuit also alleges that insulin manufacturers and pharmacy-benefit managers inflated insulin prices, adding regulatory and reputational risk. Eli Lilly insulin pricing lawsuit

About Eli Lilly and Company

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company that discovers, develops, manufactures and markets medicines for a range of medical conditions. Its major therapeutic areas include diabetes and obesity, oncology, immunology, neuroscience and cardiovascular health.

The company’s portfolio includes Mounjaro and Trulicity for diabetes, Zepbound for chronic weight management, Humalog insulin, Taltz for inflammatory diseases, Verzenio for certain breast cancers and Kisunla for early symptomatic Alzheimer’s disease.